The Value of Serum MicroRNA-21-5p and LncRNAgadd7 Express... | NCT06825754

Studies
The Value of Serum MicroRNA-21-5p and LncRNAgadd7 Expression Levels in Predicting the Severity and Prognosis of ARDS ( Acute Respiratory Distress Syndrome )

NCT06825754

Sponsor

Shao Yuekai

Status

Completed

Last Update Posted

Feb 13, 2025Actual

Enrollment

110Actual

Phase

Not provided

Conditions

Acute Respiratory Distress Syndrome

Interventions

Not provided

Countries

China

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Feb 2025

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Nov 1, 2023Actual

Primary Completion Date

Nov 30, 2024Actual

Completion Date

Jan 10, 2025Actual

First Submitted Date

Feb 7, 2025

First Submission Date that Met QC Criteria

Feb 7, 2025

First Posted Date

Feb 13, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Feb 7, 2025

Last Update Posted Date

Feb 13, 2025Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

By measuring the expression levels of MicroRNA-21-5p (miR-21-5p) and LncRNAgadd7 in the peripheral blood of ARDS patients, the study aims to explore the correlation between these levels and the severity and prognosis of ARDS.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

110Actual

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
The expression levels of MicroRNA-21-5p (miR-21-5p)		28 days
the expression levels of LncRNAgadd7		28 days

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Age ≥ 18 years;
Meets the Berlin Criteria for ARDS;
Diagnosed with ARDS within 48 hours;
Signed informed consent.

Exclusion Criteria:

Immunosuppressed patients: including those on immunosuppressive drugs, history of stem cell transplantation, etc.;
Patients with malignant tumors;
Pregnant women;
Patients discharged from the ICU within 48 hours;
History of chronic lung diseases.

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Patients with ARDS ( Acute Respiratory Distress Syndrome)

Sampling Method

Non-Probability Sample

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Affiliated Hospital of Zunyi Medical University		Zunyi	Guizhou	563100	China

Condition Browse Module

MeSH Terms

ID	Term
D012128	Respiratory Distress Syndrome

Ancestor Terms

ID	Term
D008171	Lung Diseases
D012140	Respiratory Tract Diseases
D012120	Respiration Disorders

Browse Leaves

Not provided

Browse Branches

Not provided

Label	Type	Description	Intervention Names
Survival Group
Death Group